What is ZenBio?
ZenBio, Inc. operates as a critical infrastructure provider for the biomedical research and cosmetics industries, specializing in the development and distribution of human and animal cell systems. Their comprehensive portfolio includes specialized culture media, serum products, and bespoke assay development services designed to streamline pre-clinical screening and drug discovery workflows. By maintaining rigorous quality standards, the firm serves as a vital partner for academic institutions and pharmaceutical entities seeking to optimize their research outcomes through reliable, high-performance biological materials.
How much funding has ZenBio raised?
ZenBio has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in ZenBio
PPP
Public-Private Partnership
What's next for ZenBio?
With the successful completion of this late-stage funding, ZenBio is poised to scale its research and development initiatives, focusing on the enhancement of its proprietary cell culture technologies. The influx of capital will likely be directed toward expanding their tissue procurement capabilities and refining their custom assay services to meet the evolving demands of the drug discovery pipeline. As the company transitions into this next phase of growth, stakeholders anticipate a strengthened market position, driven by continued innovation in cell-based research tools and a commitment to supporting the next generation of therapeutic breakthroughs.
See full ZenBio company page
